FDx Advisors Inc. acquired a new stake in Abiomed (NASDAQ:ABMD) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,007 shares of the medical equipment provider’s stock, valued at approximately $293,000.
A number of other large investors have also added to or reduced their stakes in the stock. American Century Companies Inc. boosted its stake in shares of Abiomed by 99.0% during the fourth quarter. American Century Companies Inc. now owns 963,517 shares of the medical equipment provider’s stock valued at $180,573,000 after purchasing an additional 479,375 shares in the last quarter. Perceptive Advisors LLC boosted its stake in shares of Abiomed by 315.6% during the fourth quarter. Perceptive Advisors LLC now owns 215,000 shares of the medical equipment provider’s stock valued at $40,293,000 after purchasing an additional 163,271 shares in the last quarter. Carillon Tower Advisers Inc. acquired a new stake in shares of Abiomed during the fourth quarter valued at about $29,531,000. Fred Alger Management Inc. boosted its stake in shares of Abiomed by 32.3% during the fourth quarter. Fred Alger Management Inc. now owns 499,294 shares of the medical equipment provider’s stock valued at $93,573,000 after purchasing an additional 121,810 shares in the last quarter. Finally, Standard Life Aberdeen plc acquired a new stake in shares of Abiomed during the fourth quarter valued at about $20,107,000. 88.02% of the stock is currently owned by institutional investors and hedge funds.
In other news, Director Martin P. Sutter sold 21,890 shares of the firm’s stock in a transaction dated Tuesday, May 8th. The stock was sold at an average price of $343.50, for a total transaction of $7,519,215.00. Following the completion of the transaction, the director now directly owns 46,668 shares in the company, valued at $16,030,458. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP William J. Bolt sold 22,790 shares of the firm’s stock in a transaction dated Monday, May 7th. The stock was sold at an average price of $348.03, for a total value of $7,931,603.70. Following the transaction, the senior vice president now owns 66,414 shares of the company’s stock, valued at $23,114,064.42. The disclosure for this sale can be found here. Insiders have sold 82,180 shares of company stock valued at $26,949,944 over the last 90 days. 7.00% of the stock is owned by corporate insiders.
Shares of Abiomed opened at $379.94 on Friday, according to MarketBeat Ratings. Abiomed has a 1 year low of $377.11 and a 1 year high of $386.45. The stock has a market cap of $16.91 billion, a PE ratio of 159.82, a P/E/G ratio of 4.12 and a beta of 0.18.
Abiomed (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, May 3rd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.16. Abiomed had a return on equity of 17.58% and a net margin of 18.89%. The company had revenue of $174.44 million during the quarter, compared to the consensus estimate of $164.30 million. During the same period last year, the company earned $0.33 earnings per share. The firm’s revenue was up 39.9% compared to the same quarter last year. research analysts predict that Abiomed will post 3.43 EPS for the current fiscal year.
ABMD has been the topic of a number of recent research reports. Zacks Investment Research raised Abiomed from a “hold” rating to a “strong-buy” rating and set a $335.00 price target on the stock in a research note on Tuesday, April 3rd. Goldman Sachs initiated coverage on Abiomed in a research note on Wednesday, April 4th. They set a “buy” rating and a $332.00 price target on the stock. Morgan Stanley lifted their price target on Abiomed from $259.00 to $320.00 and gave the company an “equal weight” rating in a research note on Tuesday, May 1st. ValuEngine raised Abiomed from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, BidaskClub raised Abiomed from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 20th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $325.00.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abiomed (NASDAQ:ABMD).
Receive News & Ratings for Abiomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed and related companies with MarketBeat.com's FREE daily email newsletter.